

Childhood Vaccine Availability Table

Eligibility Categories:

- **All Children:** Vaccine provided by MDPH for identified cohorts, regardless of insurance status.
- **Vaccines for Children (VFC) Program Only:** Vaccine provided by MDPH for identified cohorts who are: 1) uninsured; 2) enrolled in MassHealth/Medicaid; 3) American Indian or Alaska Native; or 4) underinsured (insurance does not cover the vaccine) and seen at a federally qualified community health center. (Vaccines available only for VFC eligible groups appear shaded)

Vaccine	Eligibility	DPH-Supplied Vaccine Available For:
DT	All	<ul style="list-style-type: none"> • Children aged 2 months – 6 years for whom pertussis vaccine is contraindicated
DTaP	All	<ul style="list-style-type: none"> • All children aged 2 months – 6 years
DTaP-Hep B-IPV (Pediarix®)	All	<ul style="list-style-type: none"> • All children aged 2 months – 6 years for the first 3 doses of DTaP and IPV and any dose of Hep B at 2, 4 and 6 months • Not approved for dose 4 or 5 of the DTaP series <u>or</u> dose 4 of the IPV series
DTaP-IPV-Hib (Pentacel®)	All	<ul style="list-style-type: none"> • All children aged 2 months – 4 years for the first 4 doses of DTaP, IPV and Hib at 2, 4, 6 and 15 – 18 months
DTaP-IPV (Kinrix®)	All	<ul style="list-style-type: none"> • All children aged 4 – 6 years for routine immunization for the 5th dose of the DTaP series and 4th dose of the IPV series • Not approved for the first 3 doses of DTaP and IPV <u>or</u> dose 4 of the DTaP series
Hep A	All	<ul style="list-style-type: none"> • Routine vaccination of the 1st and 2nd dose for children aged 12 – 23 months • Catch-up vaccination of children aged 2 – 18 years
Hep B	All	<ul style="list-style-type: none"> • All children through 18 years of age
Hib	All	<ul style="list-style-type: none"> • All children aged 2 – 59 months • Children aged > 5 years in an ACIP-recommended group¹
HPV	All	<ul style="list-style-type: none"> • All children 9 – 18 years of age <p>Note: routinely recommended at 7th grade entry, 11 – 12 years of age</p>
Influenza	All	<ul style="list-style-type: none"> • All children aged 6 months through 18 years
MCV4-ACWY (Meningococcal Conjugate) <small>(MDPH does not provide meningococcal polysaccharide vaccine)</small>	All	<ul style="list-style-type: none"> • All adolescents 11 – 18 years of age <p>Note: first dose routinely recommended at 7th grade entry, 11 – 12 years of age, and second dose at 16 – 18 years of age</p> <ul style="list-style-type: none"> • High risk¹ children 2 months - 18 years, all doses, including boosters. Schedule depends on age and formulation. Note: Menveo approved beginning at 2 months and Menactra at 9 months. High risk includes: functional or anatomic asplenia (sickle cell), complement deficiencies, travelers, occupational risk, outbreaks.

Vaccine	Eligibility	DPH Supplied Vaccine Available For:
MenB	All	<p>High risk children 10 – 18 years of age in the following risk groups:</p> <ul style="list-style-type: none"> • Persistent complement component deficiencies (including: inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab [Soliris®]). • Anatomic or functional asplenia (including: sickle cell). • Microbiologists routinely exposed to isolates of <i>Neisseria meningitidis</i>. • Identified as at increased risk because of a serogroup B meningococcal disease outbreak. <p>Children enrolled in Children’s Medical Security Plan (CMSP) and sCHIP are also covered using <i>state</i> funds.</p>
	VFC Only ²	<ul style="list-style-type: none"> • May be considered for healthy adolescents 16 – 18 years of age to provide short term protection against most strains of serogroup B meningococcal disease (individual clinical decision-making).
MMR	All	<ul style="list-style-type: none"> • All children aged 12 months – 18 years
MMRV	All	<ul style="list-style-type: none"> • All children aged 12 months – 12 years who require both MMR and varicella vaccines <p><u>Note:</u> ACIP recommends the 1st dose in the series for children 12 – 47 months be given as separate injections of MMR and varicella vaccines and generally recommends MMRV for the 2nd dose in the series or for the 1st dose for those ≥ 48 months. See ACIP statement for full guidance.</p>
PCV13 (Pneumococcal Conjugate)	All	<ul style="list-style-type: none"> • All children aged 2 – 59 months • High risk¹ children through age 71 months • Subset of highest risk children aged 6 – 18 years
PPSV23 (Pneumococcal Polysaccharide)	All	<ul style="list-style-type: none"> • Children aged 2 – 18 years who are in an ACIP recommended group¹
Polio	All	<ul style="list-style-type: none"> • All children aged 2 months – 18 years
Rotavirus	All	<ul style="list-style-type: none"> • All infants aged 6 weeks – 8 months 0 days
Td	All	<ul style="list-style-type: none"> • All children aged 7 – 18 years
Tdap	All	<ul style="list-style-type: none"> • All children aged 7 – 18 years <p>Note: routinely recommended at 7th grade entry, 11 – 12 years of age</p>
Varicella	All	<ul style="list-style-type: none"> • All children aged 12 months – 18 years

¹High risk children as defined by the ACIP, including those exposed in an outbreak setting who are not fully vaccinated. For a list of vaccines and the groups for whom vaccine is recommended, please see the MDPH *Summary of Advisory Committee on Immunization Practices (ACIP) Recommended Groups for Vaccination*. For the complete ACIP recommendations, see <http://www.cdc.gov/vaccines/acip/index.html>.

²Children with Medicaid as secondary insurance would be considered VFC-eligible.